Information  X 
Enter a valid email address

Genedrive PLC (GDR)

  Print      Mail a friend       Annual reports

Friday 07 December, 2018

Genedrive PLC

Result of GM

RNS Number : 8655J
Genedrive PLC
07 December 2018

7 December 2018

genedrive plc ("genedrive" or the "Company")

Result of General Meeting

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that at the General Meeting held earlier today, all the resolutions proposed were duly passed.

The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 19 November 2018 which is available on the Company's website

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 15,217,391 Placing Shares.  It is expected that Admission will become effective at 8.00 a.m. on 10 December 2018.  Following Admission, the Company will have 34,000,506 Ordinary Shares in issue. No shares have been issued under the Broker Option.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular.

-  Ends -

For further details please contact:


genedrive plc

David Budd: CEO

Matthew Fowler: CFO

+44 (0)161 989 0245

Peel Hunt LLP

James Steel

Oliver Jackson

+44 (0)207 418 8900

Stanford Capital Partners Limited

Patrick Claridge

+44 (0)203 815 8880

John Howes

Consilium Strategic Communications

Chris Gardner

Matthew Neal

Laura Thornton

+44 (0) 203 709 5700

[email protected]


Notes to Editors


About genedrive

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: and The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t